Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of AD04 (Ondansetron) in Adults With Alcohol Use Disorder (AUD) and Selected Polymorphisms in the Serotonin Transporter and Receptor Genes
Status: Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 07 Oct 2019
Price : $35 *
At a glance
- Drugs Ondansetron (Primary)
- Indications Alcoholism
- Focus Registrational; Therapeutic Use
- Acronyms ONWARD
- Sponsors ADial Pharmaceuticals
- 07 Oct 2019 According to an Adial Pharmaceuticals media release, Just last week, company filed Clinical Trial Application (CTA) in Sweden and plan to file similar applications in 6 additional European countries in the coming weeks.
- 23 Sep 2019 Status changed from planning to not yet recruiting.
- 26 Feb 2019 According to an ADial Pharmaceuticals media release, the company intends to use public offerings to fully fund this trial.